# The AI-driven techbio revolution is heating up:

> Cradle, a Netherlands-based generative AI biotech startup, just raised a $73M Series B — a round that's truly big by EU standards and signals the explosive growth of AI-driven drug discovery. I see real parallels to the rise of Veeva, and the coming years promise to be game-changing.

URL: https://www.ch-healthtech.com/insights/ai-driven-techbio-revolution-heating-up
Markdown: https://www.ch-healthtech.com/insights/ai-driven-techbio-revolution-heating-up.md
Published: 2024-11-28
Updated: 2026-05-06
Author: Christian Hein
Tags: technology/generative-ai, industry/tech-bio, technology/saas, activity/series-a-seed-funding, geography/europe, function/innovation-management

---


The AI-driven techbio revolution is heating up:

Cradle, a Netherlands-based generative AI biotech startup, has just raised an impressive $73M Series B led by Silicon Valley VC giant IVP, alongside Index Ventures and Kindred Capital VC. This comes only a year after their $23M Series A - highlighting the explosive growth and appetite for AI solutions in drug discovery and development.

This round is truly big by EU standards. It's encouraging to see Europe holding its ground and competing fiercely with the US and Israel in this space.

The SaaS-driven transformation of drug discovery and development is a market to watch, with parallels to the rise of players like Veeva in the commercial and marketing arena (and increasingly betting on the R&D space as well). The coming years promise to be game-changing.